JP2020510043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510043A5 JP2020510043A5 JP2019549420A JP2019549420A JP2020510043A5 JP 2020510043 A5 JP2020510043 A5 JP 2020510043A5 JP 2019549420 A JP2019549420 A JP 2019549420A JP 2019549420 A JP2019549420 A JP 2019549420A JP 2020510043 A5 JP2020510043 A5 JP 2020510043A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- receptor antagonist
- pharmaceutically acceptable
- acceptable salt
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002464 receptor antagonist Substances 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 20
- 239000011780 sodium chloride Substances 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 18
- 238000004519 manufacturing process Methods 0.000 claims 14
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 238000007920 subcutaneous administration Methods 0.000 claims 9
- -1 (R) -2 - {[6 - ((S) -3- methoxy - pyrrolidin-1-yl) -2-phenyl - pyrimidin-4-carbonyl] - amino } -3-phosphono - propionyl Chemical group 0.000 claims 4
- 208000010125 Myocardial Infarction Diseases 0.000 claims 4
- 208000007322 Death, Sudden, Cardiac Diseases 0.000 claims 3
- 206010061256 Ischaemic stroke Diseases 0.000 claims 3
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 3
- 206010049418 Sudden cardiac death Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- FYXHWMQPCJOJCH-GMAHTHKFSA-N selatogrel Chemical compound C1CN(C(=O)OCCCC)CCN1C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(N2C[C@H](CC2)OC)=NC(C=2C=CC=CC=2)=N1 FYXHWMQPCJOJCH-GMAHTHKFSA-N 0.000 claims 3
- 206010001902 Amaurosis Diseases 0.000 claims 2
- 206010044390 Transient ischaemic attack Diseases 0.000 claims 2
- 230000001154 acute Effects 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- AILAQOYFPLQIFN-UHFFFAOYSA-N butyl piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCNCC1 AILAQOYFPLQIFN-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 206010000891 Acute myocardial infarction Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 230000001052 transient Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023008155A JP2023052576A (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| EPPCT/EP2017/056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008155A Division JP2023052576A (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510043A JP2020510043A (ja) | 2020-04-02 |
| JP2020510043A5 true JP2020510043A5 (pt-PT) | 2021-04-22 |
Family
ID=61899166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549420A Pending JP2020510043A (ja) | 2017-03-15 | 2018-03-14 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
| JP2023008155A Pending JP2023052576A (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008155A Pending JP2023052576A (ja) | 2017-03-15 | 2023-01-23 | Ｐ２ｙ１２受容体アンタゴニストの皮下投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11179390B2 (pt-PT) |
| EP (1) | EP3595666A1 (pt-PT) |
| JP (2) | JP2020510043A (pt-PT) |
| KR (1) | KR102510832B1 (pt-PT) |
| CN (1) | CN110381947A (pt-PT) |
| AU (1) | AU2018234056B2 (pt-PT) |
| BR (1) | BR112019014567A2 (pt-PT) |
| CA (1) | CA3050831A1 (pt-PT) |
| CL (1) | CL2019002318A1 (pt-PT) |
| EA (1) | EA201992123A1 (pt-PT) |
| IL (1) | IL269286B2 (pt-PT) |
| MA (1) | MA49887A (pt-PT) |
| MX (1) | MX2019009559A (pt-PT) |
| PH (1) | PH12019502111A1 (pt-PT) |
| SG (1) | SG11201908128YA (pt-PT) |
| TW (1) | TWI765002B (pt-PT) |
| UA (1) | UA125531C2 (pt-PT) |
| WO (1) | WO2018167139A1 (pt-PT) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY193080A (en) | 2016-09-22 | 2022-09-26 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| KR20230041732A (ko) | 2020-07-15 | 2023-03-24 | 이도르시아 파마슈티컬스 리미티드 | P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물 |
| JP2024524658A (ja) | 2021-07-13 | 2024-07-05 | イドルシア・ファーマシューティカルズ・リミテッド | ４－（（ｒ）－２－｛［６－（（ｓ）－３－メトキシ－ピロリジン－１－イル）－２－フェニル－ピリミジン－４－カルボニル］－アミノ｝－３－ホスホノ－プロピオニル）－ピペラジン－１－カルボン酸ブチルエステルの合成方法 |
| WO2023174810A1 (en) | 2022-03-14 | 2023-09-21 | Idorsia Pharmaceuticals Ltd | A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870035A (en) | 1970-07-17 | 1975-03-11 | Survival Technology | Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| US5078680A (en) | 1984-08-08 | 1992-01-07 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| GR861289B (en) | 1985-05-20 | 1986-09-16 | Survival Technology | Injection method and apparatus with electrical blood absorbing stimulation |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| KR20050085580A (ko) | 2002-12-11 | 2005-08-29 | 쉐링 악티엔게젤샤프트 | 혈소판 아데노신 디포스페이트 수용체 길항제로서의2-아미노카르보닐-퀴놀린 화합물 |
| CN1863810B (zh) | 2003-04-09 | 2010-12-01 | 惠氏公司 | [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用 |
| AU2003249865A1 (en) * | 2003-06-24 | 2005-01-21 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CA2623213C (en) | 2005-10-21 | 2014-01-14 | Actelion Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| MY153427A (en) | 2007-04-23 | 2015-02-13 | Sanofi Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
| KR20100029746A (ko) | 2007-05-02 | 2010-03-17 | 포톨라 파마슈티컬스, 인코포레이티드 | 직접 작용하는 가역적인 ｐ2ｙ12 억제제의 정맥내 및 경구 투여 |
| ES2388958T3 (es) | 2007-11-29 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12 |
| JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 |
| JP5504171B2 (ja) | 2007-12-26 | 2014-05-28 | サノフイ | Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| MA33260B1 (fr) | 2009-04-08 | 2012-05-02 | Actelion Pharmaceuticals Ltd | 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines |
| CN102405220B (zh) | 2009-04-22 | 2015-05-27 | 埃科特莱茵药品有限公司 | 噻唑衍生物及其作为p2y12受体拮抗剂的用途 |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2011160768A1 (en) | 2010-06-23 | 2011-12-29 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
| MY193080A (en) | 2016-09-22 | 2022-09-26 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
-
2018
- 2018-03-14 MX MX2019009559A patent/MX2019009559A/es unknown
- 2018-03-14 CN CN201880017104.XA patent/CN110381947A/zh active Pending
- 2018-03-14 EP EP18715499.2A patent/EP3595666A1/en active Pending
- 2018-03-14 EA EA201992123A patent/EA201992123A1/ru unknown
- 2018-03-14 UA UAA201910293A patent/UA125531C2/uk unknown
- 2018-03-14 KR KR1020197029753A patent/KR102510832B1/ko active IP Right Grant
- 2018-03-14 AU AU2018234056A patent/AU2018234056B2/en active Active
- 2018-03-14 BR BR112019014567-2A patent/BR112019014567A2/pt unknown
- 2018-03-14 CA CA3050831A patent/CA3050831A1/en active Pending
- 2018-03-14 TW TW107108546A patent/TWI765002B/zh active
- 2018-03-14 WO PCT/EP2018/056372 patent/WO2018167139A1/en unknown
- 2018-03-14 JP JP2019549420A patent/JP2020510043A/ja active Pending
- 2018-03-14 SG SG11201908128Y patent/SG11201908128YA/en unknown
- 2018-03-14 MA MA049887A patent/MA49887A/fr unknown
- 2018-03-14 US US16/494,254 patent/US11179390B2/en active Active
-
2019
- 2019-08-16 CL CL2019002318A patent/CL2019002318A1/es unknown
- 2019-09-11 IL IL269286A patent/IL269286B2/en unknown
- 2019-09-13 PH PH12019502111A patent/PH12019502111A1/en unknown
-
2023
- 2023-01-23 JP JP2023008155A patent/JP2023052576A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (pt-PT) | ||
| JP2020510043A5 (pt-PT) | ||
| JP2020033360A5 (pt-PT) | ||
| Doepker et al. | High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and beta-blocker overdose: a case series | |
| JP2011173928A5 (pt-PT) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2018513188A5 (pt-PT) | ||
| JP2009102342A5 (pt-PT) | ||
| JP2010526101A5 (pt-PT) | ||
| HRP20221100T1 (hr) | Stabilna parenteralna formulacija nimopidina | |
| JP2014516942A5 (pt-PT) | ||
| JP2019517542A5 (pt-PT) | ||
| ES2971959T3 (es) | Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013518124A5 (pt-PT) | ||
| JP2017533211A5 (pt-PT) | ||
| JP2016505050A5 (pt-PT) | ||
| ES2704229T3 (es) | Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia | |
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| JP2012526099A5 (pt-PT) | ||
| JP2008526816A5 (pt-PT) | ||
| JP2003160509A (ja) | 乳癌の治療 | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| JP2019509309A5 (pt-PT) | ||
| TWI631944B (zh) | 氯硝柳胺及其衍生物的用途 |